With $170.4M in cash and a Phase 3 trial now enrolling, the stock will trade on enrollment updates and eventual data readouts rather than quarterly financials. The EPS miss is marginal and typical for pre-revenue biotechs — the key catalyst to watch is the pace of site activations and patient enrollment in IMPROVE-PAH over the next 6-12 months.
Price Chart
Executive Summary
Inhibikase Therapeutics reported Q1 2026 results with a net loss of $16.4M ($0.10/share), slightly wider than the $13.7M loss in Q1 2025 and a $0.01 miss vs consensus. The pre-revenue clinical-stage company highlighted first patient enrollment in its pivotal Phase 3 IMPROVE-PAH study and regulatory approvals in 16 countries, but the widening cash burn and absence of near-term revenue catalysts keep the stock driven by trial execution milestones rather than financials.
Key Financial Metrics
Key Facts
- Net loss of $16.4M ($0.10/share) vs $13.7M ($0.15/share) in Q1 2025; consensus was $-0.09
- Cash, cash equivalents and marketable securities at $170.4M as of March 31, 2026, down from $178.8M at year-end 2025
- First patient enrolled in global pivotal Phase 3 IMPROVE-PAH study in April 2026
- Regulatory approvals received in 16 countries including US, Canada, EU (12 countries), New Zealand, and Argentina
- Orphan Drug Designation application submitted to FDA for IKT-001 in PAH
- R&D expenses $10.8M vs $10.5M in Q1 2025; SG&A $7.4M vs $5.2M
- Cash used in operations $12.1M vs $4.1M in Q1 2025, reflecting increased trial activity
Financial Impact
Net loss of $16.4M, cash burn of $12.1M from operations; no revenue reported
Risk Factors
- Phase 3 trial enrollment delays or slower-than-expected site activations
- Cash burn accelerating as trial scales up; $170.4M may fund ~2.5 years at current burn rate
- No revenue or near-term commercialization path; binary event risk on trial outcomes
- Potential need for additional capital before trial completion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219610 |
| Document: d119997d8k.htm | 0001193125-26-219610 |
| Document: 0001193125-26-219610-index-headers.html | 0001193125-26-219610 |
| Document: 0001193125-26-219610-index.html | 0001193125-26-219610 |
| Document: 0001193125-26-219610.txt | 0001193125-26-219610 |
| 8-K Data (Synthetic) | 0001193125-26-219610 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.66 | awaiting T+20 | — | $1.57 (−5.42%) |
Oct 2, 2026 25d ago | Press Release | $2.00 | awaiting T+20 | — | $1.57 (−21.50%) |
Aug 11, 2026 11w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.57 (−34.58%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.57 (−32.62%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.57 (−29.60%) |
Jul 14, 2026 15w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.57 (+23.79%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.57 (−18.65%) |
May 12, 2026 23w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
May 12, 2026 24w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
Apr 7, 2026 29w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.57 (−10.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers